|Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist|
AJ van der Lely, RK Hutson, PJ Trainer, GM Besser, AL Barkan, ...
The Lancet 358 (9295), 1754-1759, 2001
|Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure|
A Colao, R Pivonello, S Spiezia, A Faggiano, D Ferone, M Filippella, ...
The Journal of Clinical Endocrinology & Metabolism 84 (8), 2664-2672, 1999
|Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia|
A Colao, A Di Sarno, P Cappabianca, C Di Somma, R Pivonello, ...
New England Journal of Medicine 349 (21), 2023-2033, 2003
|Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission|
A Faggiano, R Pivonello, S Spiezia, MC De Martino, M Filippella, ...
The Journal of Clinical Endocrinology & Metabolism 88 (6), 2527-2533, 2003
|Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy|
A Di Sarno, ML Landi, P Cappabianca, F Di Salle, FW Rossi, R Pivonello, ...
The Journal of Clinical Endocrinology & Metabolism 86 (11), 5256-5261, 2001
|The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery|
R Pivonello, MC De Martino, P Cappabianca, M De Leo, A Faggiano, ...
The Journal of Clinical Endocrinology & Metabolism 94 (1), 223-230, 2009
|The theory of constructed emotion: an active inference account of interoception and categorization|
Social cognitive and affective neuroscience 12 (1), 1-23, 2017
|Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients|
A Colao, A Di Sarno, ML Landi, F Scavuzzo, P Cappabianca, R Pivonello, ...
The Journal of Clinical Endocrinology & Metabolism 85 (6), 2247-2252, 2000
|Dopamine receptor expression and function in corticotroph pituitary tumors|
R Pivonello, D Ferone, WW De Herder, JM Kros, ML Del Basso De Caro, ...
The Journal of Clinical Endocrinology & Metabolism 89 (5), 2452-2462, 2004
|Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly|
A Colao, R Attanasio, R Pivonello, P Cappabianca, LM Cavallo, G Lasio, ...
The Journal of Clinical Endocrinology & Metabolism 91 (1), 85-92, 2006
|Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism|
A Colao, C Di Somma, R Pivonello, S Loche, G Aimaretti, G Cerbone, ...
The Journal of Clinical Endocrinology & Metabolism 84 (6), 1919-1924, 1999
|Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia|
A Colao, AD Sarno, P Cappabianca, F Briganti, R Pivonello, CD Somma, ...
European Journal of Endocrinology 148 (3), 325-331, 2003
|Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage|
A Colao, A Di Sarno, ML Landi, S Cirillo, F Sarnacchiaro, G Facciolli, ...
The Journal of Clinical Endocrinology & Metabolism 82 (11), 3574-3579, 1997
|Resistance to somatostatin analogs in acromegaly|
A Colao, RS Auriemma, G Lombardi, R Pivonello
Endocrine reviews 32 (2), 247-271, 2010
|Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire|
SM Webb, X Badia, MJ Barahona, A Colao, CJ Strasburger, A Tabarin, ...
European Journal of Endocrinology 158 (5), 623-630, 2008
|Prolactin and autoimmunity|
A De Bellis, A Bizzarro, R Pivonello, G Lombardi, A Bellastella
Pituitary 8 (1), 25-30, 2005
|The metabolic syndrome and cardiovascular risk in Cushing's syndrome|
R Pivonello, A Faggiano, G Lombardi, A Colao
Endocrinology and Metabolism Clinics 34 (2), 327-339, 2005
R Pivonello, MC De Martino, M De Leo, G Lombardi, A Colao
Endocrinology and metabolism clinics of North America 37 (1), 135-149, 2008
|Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect …|
A Colao, R Pivonello, RS Auriemma, MC De Martino, M Bidlingmaier, ...
European Journal of Endocrinology 154 (3), 467-477, 2006
|Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency|
A Colao, C Di Somma, A Cuocolo, L Spinelli, N Tedesco, R Pivonello, ...
The Journal of Clinical Endocrinology & Metabolism 86 (5), 1874-1881, 2001